Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23194581 | 1.00 | HSD11B1 (0.42) | HSD11B1AAK1STK17BIDO1CLK1 | |
| SCHEMBL22049846 | 0.92 | STING1 (0.42) | HSD11B1AAK1STK17BIDO1CLK1 | |
| SCHEMBL23625742 | 0.91 | STING1 (0.42) | HSD11B1AAK1STK17BIDO1CLK1 | |
| SCHEMBL23207730 | 0.84 | IDO1 (0.37) | HSD11B1AAK1STK17BIDO1HDAC2 | |
| SCHEMBL23612079 | 0.84 | STING1 (0.42) | HSD11B1AAK1IDO1CLK1DYRK1A | |
| SCHEMBL30267628 | 0.82 | HSD11B1 (0.42) | HSD11B1AAK1IDO1CLK1DYRK1A | |
| SCHEMBL23625725 | 0.82 | HSD11B1 (0.42) | HSD11B1AAK1IDO1CLK1DYRK1A | |
| SCHEMBL23625787 | 0.79 | STING1 (0.41) | HSD11B1AAK1IDO1CLK1DYRK1A | |
| SCHEMBL23194437 | 0.79 | CDK5 (0.36) | PTPN2PTPN1CDK2 | |
| SCHEMBL30176010 | 0.79 | CDK5 (0.36) | PTPN2PTPN1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002373-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | HSD11B1 3262/4885AAK1 1490/4885STK17B 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.